FI3281939T3 - Yhdistelmä, joka sisältää 4-oksokinoliiniyhdisteen stabiilin kiteen - Google Patents

Yhdistelmä, joka sisältää 4-oksokinoliiniyhdisteen stabiilin kiteen Download PDF

Info

Publication number
FI3281939T3
FI3281939T3 FIEP17186674.2T FI17186674T FI3281939T3 FI 3281939 T3 FI3281939 T3 FI 3281939T3 FI 17186674 T FI17186674 T FI 17186674T FI 3281939 T3 FI3281939 T3 FI 3281939T3
Authority
FI
Finland
Prior art keywords
crystal
powder
combination
pharmaceutical composition
stable crystal
Prior art date
Application number
FIEP17186674.2T
Other languages
English (en)
Finnish (fi)
Inventor
Motohide Satoh
Takahisa Motomura
Takashi Matsuda
Kentaro Kondo
Koji Ando
Koji Matsuda
Shuji Miyake
Hideto Uehara
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3281939(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Application granted granted Critical
Publication of FI3281939T3 publication Critical patent/FI3281939T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
FIEP17186674.2T 2004-05-20 2005-05-19 Yhdistelmä, joka sisältää 4-oksokinoliiniyhdisteen stabiilin kiteen FI3281939T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004150979 2004-05-20

Publications (1)

Publication Number Publication Date
FI3281939T3 true FI3281939T3 (fi) 2023-10-23

Family

ID=35079161

Family Applications (2)

Application Number Title Priority Date Filing Date
FIEP17186674.2T FI3281939T3 (fi) 2004-05-20 2005-05-19 Yhdistelmä, joka sisältää 4-oksokinoliiniyhdisteen stabiilin kiteen
FIC20240008C FIC20240008I1 (fi) 2004-05-20 2024-03-20 Elvitegraviiri ja tenofoviirialafenamidi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FIC20240008C FIC20240008I1 (fi) 2004-05-20 2024-03-20 Elvitegraviiri ja tenofoviirialafenamidi

Country Status (33)

Country Link
US (7) US7635704B2 (OSRAM)
EP (4) EP2514746A1 (OSRAM)
JP (1) JP3754064B2 (OSRAM)
KR (1) KR20080064909A (OSRAM)
CN (1) CN1956961B (OSRAM)
AR (2) AR049280A1 (OSRAM)
AU (1) AU2005245296B2 (OSRAM)
BE (1) BE2024C511I2 (OSRAM)
BR (1) BRPI0510114B8 (OSRAM)
CA (1) CA2566922C (OSRAM)
CY (4) CY1113010T1 (OSRAM)
DK (2) DK1636190T3 (OSRAM)
ES (2) ES2960824T3 (OSRAM)
FI (2) FI3281939T3 (OSRAM)
FR (1) FR23C1040I1 (OSRAM)
HR (2) HRP20231588T3 (OSRAM)
HU (2) HUE064615T2 (OSRAM)
IL (1) IL179250A0 (OSRAM)
LT (2) LT3281939T (OSRAM)
LU (1) LUC00334I2 (OSRAM)
MX (1) MXPA06013405A (OSRAM)
MY (1) MY134672A (OSRAM)
NO (8) NO339223B1 (OSRAM)
NZ (1) NZ551839A (OSRAM)
PE (2) PE20120361A1 (OSRAM)
PL (2) PL3281939T3 (OSRAM)
PT (2) PT1636190E (OSRAM)
RS (2) RS64845B1 (OSRAM)
RU (1) RU2330845C1 (OSRAM)
SI (2) SI3281939T1 (OSRAM)
TW (1) TWI329015B (OSRAM)
WO (1) WO2005113508A1 (OSRAM)
ZA (1) ZA200610647B (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891227B2 (en) 2002-03-20 2005-05-10 International Business Machines Corporation Self-aligned nanotube field effect transistor and method of fabricating same
DE60329318D1 (de) * 2002-11-20 2009-10-29 Japan Tobacco Inc 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
SG170795A1 (en) * 2005-12-30 2011-05-30 Gilead Sciences Inc Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090018162A1 (en) * 2006-02-01 2009-01-15 Yuji Matsuzaki Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
CN101437801B (zh) 2006-03-06 2013-02-06 日本烟草产业株式会社 制备4-氧代喹啉化合物的方法
BRPI0708685B8 (pt) * 2006-03-06 2021-05-25 Japan Tobacco Inc composto de 4-oxoquinolina, seu uso e método para produção dos mesmos
ME02258B (me) 2006-07-07 2015-12-31 Gilead Sciences Inc Modulatori farmakokinetičkih svojstava terapeutika
TWI411602B (zh) 2006-09-12 2013-10-11 Gilead Sciences Inc 製造整合酶抑制劑的方法及彼所用的中間物
PL2487161T5 (pl) * 2007-02-23 2024-09-09 Gilead Sciences, Inc. <div>Modulatory właściwości farmakokinetycznych środków terapeutycznych</div><div> </div>
NZ582089A (en) * 2007-06-29 2013-01-25 Gilead Sciences Inc Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
TW200914011A (en) * 2007-06-29 2009-04-01 Gilead Sciences Inc Therapeutic compositions and methods
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
PL2296633T3 (pl) 2008-05-02 2016-03-31 Gilead Sciences Inc Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego
AP3250A (en) 2009-02-06 2015-05-31 Gilead Sciences Inc Tablets for combination therapy
WO2010137032A2 (en) * 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
CN102212032B (zh) * 2011-04-20 2013-07-31 复旦大学 一种5-羟基喹诺酮类衍生物及其制备方法和用途
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
AU2013296289B2 (en) 2012-08-03 2017-10-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
CN103819402B (zh) * 2012-11-17 2016-03-30 上海迪赛诺化学制药有限公司 埃替拉韦中间体及其制备方法和应用
CN103864682B (zh) * 2012-12-18 2016-12-28 上海迪赛诺化学制药有限公司 一种制备iii型埃替拉韦晶体的方法
PE20151499A1 (es) 2012-12-21 2015-10-29 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico
EP3252058B1 (en) 2013-07-12 2021-01-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2865735T3 (OSRAM) 2013-07-12 2018-07-21
CN105315203A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种v型埃替拉韦晶体及其制备方法
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (OSRAM) 2014-06-20 2018-06-23
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
KR20190057158A (ko) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
CN106008195B (zh) * 2016-05-19 2018-08-03 绍兴文理学院 一种2，4-二氟-5-碘苯甲酸的制备方法
EP3984536B1 (en) * 2020-10-19 2025-06-25 Centre national de la recherche scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS567162B1 (OSRAM) 1970-09-14 1981-02-16
JPS4826772A (OSRAM) 1971-08-11 1973-04-09
JPS6450979A (en) 1987-08-21 1989-02-27 Hitachi Shipbuilding Eng Co Method for discriminating whistle sound
JPH0651229B2 (ja) 1989-07-31 1994-07-06 新日本製鐵株式会社 プラズマアーク溶接方法および装置
IL100555A (en) * 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
NO304832B1 (no) * 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
HUT76643A (en) * 1994-07-18 1997-10-28 Sankyo Co Trifluoromethylquinolinecarboxylic acid derivative, pharmaceutical compositions containing them and their use
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
ES2171260T3 (es) 1996-04-12 2002-09-01 Us Gov Health & Human Serv Compuestos derivados de acridona utiles como agentes antineoplasicos y antirretroviricos.
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
GB9721964D0 (en) * 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
PE20011349A1 (es) * 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
EP1326610B1 (en) 2000-10-12 2006-11-15 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
WO2002036734A2 (en) 2000-10-12 2002-05-10 Merck & Co., Inc. Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
IL157638A0 (en) 2001-03-01 2004-03-28 Shionogi & Co Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
FR2827600A1 (fr) 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
RU2206564C1 (ru) * 2002-03-07 2003-06-20 Общество с ограниченной ответственностью "Поливит" Способ получения этилового эфира 6-фтор-7-хлор-1,4-дигидро-4-оксо-3-хинолинкарбоновой кислоты
JP4035765B2 (ja) 2002-10-31 2008-01-23 横河電機株式会社 フーリエ変換型赤外線分光計
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
DE60329318D1 (de) * 2002-11-20 2009-10-29 Japan Tobacco Inc 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
EP3287130A1 (en) * 2004-05-21 2018-02-28 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and protease inhibitors

Also Published As

Publication number Publication date
BRPI0510114B1 (pt) 2020-09-15
PE20120361A1 (es) 2012-05-03
RS64845B1 (sr) 2023-12-29
HUS2400006I1 (hu) 2024-04-28
HRP20231588T3 (hr) 2024-03-15
JP2006001927A (ja) 2006-01-05
LT3281939T (lt) 2023-11-27
US20150361044A1 (en) 2015-12-17
SI3281939T1 (sl) 2024-02-29
CY1113010T1 (el) 2016-04-13
AU2005245296A1 (en) 2005-12-01
LUC00334I2 (OSRAM) 2024-07-01
NO20161297A1 (no) 2007-02-07
US20250091995A1 (en) 2025-03-20
US20060030710A1 (en) 2006-02-09
TW200600097A (en) 2006-01-01
MY134672A (en) 2007-12-31
LTC3281939I2 (OSRAM) 2025-04-25
IL179250A0 (en) 2007-03-08
RU2330845C1 (ru) 2008-08-10
BE2024C511I2 (OSRAM) 2024-10-08
PL1636190T3 (pl) 2012-10-31
EP2514746A1 (en) 2012-10-24
US20190185433A1 (en) 2019-06-20
SI1636190T1 (sl) 2012-09-28
US20100204271A1 (en) 2010-08-12
CY2015009I1 (el) 2024-09-20
FIC20240008I1 (fi) 2024-03-20
CN1956961B (zh) 2010-05-26
NO347902B1 (no) 2024-05-06
ZA200610647B (en) 2008-06-25
HK1083341A1 (en) 2006-06-30
MXPA06013405A (es) 2007-03-01
EP1636190B1 (en) 2012-06-27
NO339223B1 (no) 2016-11-21
US20220235009A1 (en) 2022-07-28
NO20200873A1 (no) 2007-02-07
CA2566922A1 (en) 2005-12-01
AR096100A2 (es) 2015-12-09
DK3281939T3 (da) 2024-01-22
CY2015009I2 (el) 2024-09-20
DK1636190T3 (da) 2012-09-24
JP3754064B2 (ja) 2006-03-08
NO20065790L (no) 2007-02-07
LTPA2024001I1 (OSRAM) 2024-04-10
EP4299563A2 (en) 2024-01-03
PT1636190E (pt) 2012-08-20
PE20060358A1 (es) 2006-05-12
KR20080064909A (ko) 2008-07-09
HRP20120681T1 (hr) 2012-09-30
CN1956961A (zh) 2007-05-02
PL3281939T3 (pl) 2024-03-18
CA2566922C (en) 2011-01-11
AR049280A1 (es) 2006-07-12
HUE064615T2 (hu) 2024-04-28
FR23C1040I1 (fr) 2023-12-29
US7635704B2 (en) 2009-12-22
US20180029989A1 (en) 2018-02-01
NO2024034I1 (no) 2024-07-15
EP3281939B1 (en) 2023-10-18
NO20230913A1 (no) 2007-02-07
NO20190051A1 (no) 2007-02-07
AU2005245296B2 (en) 2010-08-12
NZ551839A (en) 2009-11-27
EP3281939A1 (en) 2018-02-14
RS52375B (sr) 2012-12-31
NO20220690A1 (no) 2007-02-07
PT3281939T (pt) 2023-11-22
WO2005113508A1 (en) 2005-12-01
EP1636190A1 (en) 2006-03-22
TWI329015B (en) 2010-08-21
ES2960824T3 (es) 2024-03-06
CY2024008I1 (el) 2024-09-20
NO20240384A1 (no) 2007-02-07
CY1126560T1 (el) 2024-09-20
BRPI0510114A (pt) 2007-09-25
US8981103B2 (en) 2015-03-17
BRPI0510114B8 (pt) 2021-05-25
CY2024008I2 (el) 2024-09-20
EP4299563A3 (en) 2024-02-28
ES2388441T3 (es) 2012-10-15

Similar Documents

Publication Publication Date Title
FI3281939T3 (fi) Yhdistelmä, joka sisältää 4-oksokinoliiniyhdisteen stabiilin kiteen
EP2234485A4 (en) STABLE LAQUINIMOD PREPARATIONS
WO2007048066A3 (en) Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
WO2008120725A1 (ja) 新規ピロリノン誘導体およびそれを含有する医薬組成物
WO2007058602A3 (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia.
CA2499330A1 (en) New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
HRP20171175T1 (hr) Novi triciklički spojevi
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
IL183583A (en) Quinazoline History and Pharmaceuticals Containing Them and Methods of Manufacturing
EP2308867A3 (en) 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
IL188643A (en) Derivatives – n (troaryl) –1 – troarylalkyl – 1h – indole – 2– carboxamide, process for the production of derivatives, drug, pharmaceutical composition and use of derivatives for drug production.
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
WO2006025070A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
TW200508197A (en) Indolone-acetamide derivatives, processes for preparing them and their uses
MX2007007098A (es) Derivados de pirrol que tienen actividad antagonista del receptor crth2.
EE200300429A (et) Tegafuri, uratsiili, foliinhappe, paklitakseeli ja karboplatiini kasutamine ravimkoostise valmistamiseks kasvaja raviks
TWI315305B (en) Piperidin-4-yl-amide derivatives,pharmaceutical compositions comprising the same,process for preparing the same and the use thereof
MY139704A (en) Naphthalene derivatives for use as histamine-3-receptor ligands
WO2006125555A3 (de) Chinazolinone
WO2009027736A3 (en) 2,4 diaminopyrimid&#39;lnes for the treatment of myeloproliferative disorders and cancer
WO2009071691A3 (de) Oxindol-derivate und ihre verwendung als medikament
TW200718698A (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
SI1742927T1 (sl) Derivati butanojske kisline, postopki za pripravo le-teh, farmacevtski sestavki, ki jih vsebujejo in terapevtske uporabe le-teh
ZA200704318B (en) Process for and intermediates in the preparation of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents
WO2005077951A3 (en) 7h-pyrrolopyrimidine derivatives